Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. ACN
7. NVDA
8. BLZE
9. IBM
10. PRIM

Go back to Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

Baird Remains Positive on Sarepta (SRPT) Amid New DMD Deal; Affirms at 'Outperform'

October 4, 2016 9:13 AM EDT

Baird affirms Sarepta Therapeutics (Nasdaq: SRPT) at Outperform with a price target of $102 following a new licensing agreement with Summit Therapeutics (Nasdaq: SMMT).

Analyst Brian Skorney noted that there was no change to the firm's outlook on Sarepta... More

Sarepta (SRPT) Deal with Summit Removes a Competitive Threat and Increases its Takeover Attractiveness - RBC

October 4, 2016 9:01 AM EDT

RBC Capital analyst Simos Simeonidis said he likes Sarepta Therapeutic (NASDAQ: SRPT) EU/LatAm partnership with Summit (NASDAQ: SMMT), as it removes a potential competitive threat with just $40M for access to competitor's drugs. He also said it makes the Sarepta more attractive as a takeover.

"Buying into this early-stage potential... More

Summit Therapeutics (SMMT) Surges 80% on Sarepta (SRPT) Deal

October 4, 2016 8:56 AM EDT

Summit Therapeutics (NASDAQ: SMMT) is trading up 80% in pre-open trade after the company entered an exclusive... More

Deal Positive for Sarepta (SRPT), Summit (SMMT) and DMD Community - Oppenheimer

October 4, 2016 8:44 AM EDT

Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and $76 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the company Sarepta and Summit (NASDAQ: SMMT) announced a licensing and collaboration agreement for EU rights to Summit's utrophin modulation programs... More